everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...2223242526272829303132...132133»
  • ||||||||||  Sulanda (surufatinib) / Hutchmed
    Review, Journal:  Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues. (Pubmed Central) -  Aug 27, 2022   
    In the current era, selection of these agents is largely based on expert opinion in the context of patient and tumor characteristics without definitive data on the preferred order of agents to administer. In this review, we aim to describe the treatment landscape of metastatic SBNETs beyond SSAs and provide an overview of novel treatments which are currently under clinical evaluation.
  • ||||||||||  everolimus / Generic mfg.
    Journal, Adverse events, Real-world evidence:  Comprehensive analysis of everolimus-induced adverse events using the Japanese real-world database. (Pubmed Central) -  Aug 26, 2022   
    A comprehensive survey of adverse events associated with everolimus administration using the pharmacovigilance database revealed that pulmonary and haematological AEs are frequently reported. The results suggest that attention should be paid to the occurrence of lung disorders because they may lead to fatal outcomes.
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Clinical, Journal:  Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. (Pubmed Central) -  Aug 25, 2022   
    Major efforts should be directed to early identify and overcome resistance and to limit toxicity. The progress in the therapeutic management of NENs grows faster and the choice of the best approach should be based on randomized clinical trials, as well as on long-term, real-world data.
  • ||||||||||  everolimus / Generic mfg.
    Biomarker, Review, Journal, Next-generation sequencing, BRCA Biomarker, PARP Biomarker, IO biomarker:  Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients. (Pubmed Central) -  Aug 24, 2022   
    25.0% (17/68) of patients had somatic mutations or copy number variations beyond BRCA1 mutations and might be treated with off-label therapy or to be allocated into clinical trial. NGS assays of HGSOC patients are necessary to screen actionable genetic alterations to guide personalized and precise treatment.
  • ||||||||||  everolimus / Generic mfg.
    Journal, BRCA Biomarker:  Targeting the mTOR Pathway for the Prevention of ER-negative Breast Cancer. (Pubmed Central) -  Aug 22, 2022   
    Everolimus treatment also reduces proliferation of normal mammary gland cells. Our results support testing everolimus in clinical trials for the prevention of ER-negative breast cancer in women at high risk of ER-negative breast cancer.
  • ||||||||||  Trial completion date, Trial primary completion date, Combination therapy:  ENCERT: Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov) -  Aug 22, 2022   
    P1,  N=15, Recruiting, 
    The contribution of mixing patient and simulated profiles was significant only when they were in balanced numbers, with ~500 for each (RMSE = 12.5 μg*h/L), compared with patient data alone (RMSE = 18.0 μg*h/L). Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
  • ||||||||||  Piqray (alpelisib) / Novartis, Ibrance (palbociclib) / Pfizer
    Journal:  Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. (Pubmed Central) -  Aug 22, 2022   
    The tumor samples expressed significantly higher levels of Cyclin D1, CDK4, p-AKT and p-4E-BP1 after progression on palbociclib treatment. In conclusion, our findings suggest that overexpressed Cyclin D1 and CDK4 proteins lead to the resistance to CDK4/6 inhibitor and PI3K/mTOR inhibitors are able to restore the sensitivity to CDK4/6 inhibitors, which provides the biomarker and rationale for the combinational use of CDK4/6 inhibitors and PI3K/mTOR inhibitors after CDK4/6 inhibitor resistance in breast cancer.
  • ||||||||||  Mekinist (trametinib) / Novartis, Darzalex (daratumumab) / J&J, Zelboraf (vemurafenib) / Roche
    Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable () -  Aug 13, 2022 - Abstract #IMW2022IMW_338;    
    Treatments: Based on these results seven patients were able to obtain off-label approval for treatment with Everolimus (Evo) (for PTEN) (Patient 1 & 11) or Trametinib (Tra) (for KRAS) (Patient 3, 5,6 & 9) in combination with Pomalidomide (PomDex) w/wo Daratumumab. Detection of clonal mutations in our experience has shown higher incidence of p53 mutations among EMD and has led us to design novel treatment options achieving transient ≥VGPR responses.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Tip-concentrated microneedle patch delivering everolimus for therapy of multiple sclerosis. (Pubmed Central) -  Aug 13, 2022   
    The therapeutic effect of everolimus-loaded microneedles was evaluated using the experimental autoimmune encephalomyelitis (EAE) model and further verified with neurological function scores and the histopathological results of the spinal cord. These results indicated that the tip-concentrated microneedle patch provided an effective, safe and simple method for the transdermal delivery of everolimus, thus providing a new treatment for multiple sclerosis.
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    PK/PD data, Review, Journal:  Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients. (Pubmed Central) -  Aug 10, 2022   
    To prevent everolimus-induced poor DM outcomes, early DM detection and treatment are necessary, and the effect of the concomitant drug should be considered before initiating everolimus treatment. The overview of the current covariates for pharmacokinetic variability of mTOR inhibitors has been provided on the level of absorption, distribution and elimination, and consequences of these relationships for dosing optimization has been summarized.
  • ||||||||||  Trial primary completion date:  FUSCC Refractory TNBC Umbrella (FUTURE) (clinicaltrials.gov) -  Aug 10, 2022   
    P1/2,  N=140, Recruiting, 
    The overview of the current covariates for pharmacokinetic variability of mTOR inhibitors has been provided on the level of absorption, distribution and elimination, and consequences of these relationships for dosing optimization has been summarized. Trial primary completion date: Jun 2022 --> Dec 2022
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Case Report: Anca-Associated Vasculitis In Post-Transplant Renal Graft (Screen # 4) -  Aug 7, 2022 - Abstract #PANLAR2022PANLAR_342;    
    Image 1 Image 2 Conclusion Systemic glucocorticoids and Rituximab treatment was initiated, plasmapheresis, immunoglobulins were administered and continued with MMF 1.5 g/day and tacrolimus 3 mg/day as renal graft preservation. After 2 weeks of follow-up, the patient was sent to hemodialysis, and 6 months later she continued in renal replacement therapy, with no partial or complete response.
  • ||||||||||  temozolomide / Generic mfg., everolimus / Generic mfg.
    Journal:  Characteristics and trends of globally registered glioma clinical trials in the past 16 years. (Pubmed Central) -  Aug 6, 2022   
    Advancement in the treatment of glioma has been vacant since temozolomide has proved its therapeutic value in glioblastoma in 2005...Only everolimus and tumor-treating fields exhibited meaningful survival benefit in specific glioma patients in phase 3 trials...Bayesian adaptive platform trials may accelerate clinical research in glioma. Development of novel treatment modalities for glioma is still challenged.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date:  Analysis of Circulating Tumor Markers in the Blood (ALCINA) (clinicaltrials.gov) -  Aug 3, 2022   
    P=N/A,  N=760, Recruiting, 
    Considering there is a mechanism of resistance to CDK4/6 inhibitors, everolimus would be important as an effective post-treatment for HR+ or HER2-negative metastatic and recurrent breast cancers treated with CDK4/6 inhibitors in clinical settings. Trial completion date: Jan 2025 --> Jul 2024
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors. (Pubmed Central) -  Aug 3, 2022   
    In recurrent tumors reoperation and radiotherapy, including stereotactic radiotherapy, can be useful. Targeted therapies may be used in selected patients: BRAF and MEK inhibitors in pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and gangliogliomas when BRAF altered, and mTOR inhibitor everolimus in subependymal giant cells astrocytomas .Sequencing to identify molecular targets is advocated for diagnostic clarification and to direct potential targeted therapies.
  • ||||||||||  tamoxifen / Generic mfg., everolimus / Generic mfg.
    Journal:  MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells. (Pubmed Central) -  Aug 3, 2022   
    Finally, expression data mining in tumors revealed a correlation between the expression of MEN1 mRNA and that of several mTORC1 components and targets, and a significant inverse correlation between MEN1 and two MYC inhibitory factors, MYCBP2 and MYCT1, in ER+ BC. The current work thus highlights altered mTORC1 and MYC pathways after menin inactivation in ER+ BC cells, providing insight into the crosstalk between menin, mTORC1 and MYC in ER+ BC.
  • ||||||||||  Phase classification, Enrollment change, Trial completion date, Trial primary completion date:  STAPOVER: Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (clinicaltrials.gov) -  Aug 2, 2022   
    P2/3,  N=148, Not yet recruiting, 
    No abstract available Phase classification: P3 --> P2/3 | N=50 --> 148 | Trial completion date: Dec 2023 --> Oct 2026 | Trial primary completion date: Aug 2023 --> Oct 2025
  • ||||||||||  dexamethasone / Generic mfg., everolimus / Generic mfg.
    Trial termination:  MIST: Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer (clinicaltrials.gov) -  Aug 1, 2022   
    P3,  N=39, Terminated, 
    Phase classification: P3 --> P2/3 | N=50 --> 148 | Trial completion date: Dec 2023 --> Oct 2026 | Trial primary completion date: Aug 2023 --> Oct 2025 Active, not recruiting --> Terminated; Severe lack of accrual
  • ||||||||||  everolimus / Generic mfg.
    Enrollment open:  Everolimus Trial in Laryngotracheal Stenosis (clinicaltrials.gov) -  Aug 1, 2022   
    P1,  N=20, Recruiting, 
    Active, not recruiting --> Terminated; Severe lack of accrual Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. (Pubmed Central) -  Jul 30, 2022   
    In preclinical work, antidiabetic drugs (metformin, GLP-1-based, GABA, PPAR-γ agonists) also enhanced Klotho...Notably, exercise and sport activity increased Klotho. This review addresses molecular, physiological and therapeutic aspects of Klotho.
  • ||||||||||  everolimus / Generic mfg.
    Preclinical, Journal:  In Vitro Interactions of Antifungal Agents and Everolimus Against Aspergillus Species. (Pubmed Central) -  Jul 30, 2022   
    In contrast, EVL exhibited minimal synergistic inhibitory activity (14.3%) when applied in combination with voriconazole (VRC)...In vivo experiments conducted in Galleria mellonella revealed that EVL in combination with antifungal agents improved the larva survival rates in the ITC, VRC, POS, and AMB groups by 18.3%, 13.3%, 26.7%, and 13.3%, respectively. These data suggest that the combination treatment with antifungal agents and antifungal agents holds promise as a means of alleviating clinical aspergillosis.